Regeneron Pharmaceuticals, Inc., Tarrytown, NY. RATIONALE: Allergic rhinitis (AR), a common type 2 comorbidity in asthma patients, contributes to increased overall disease burden. Dupilumab, a fully human VelocImmune Ò -derived anti-interleukin (IL)-4Ra mAb that inhibits IL-4 and IL-13, key drivers of type 2 inflammation, is approved for treatment of adults with inadequately controlled moderateto-severe atopic dermatitis. METHODS: Post hoc analysis of the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854) in asthma patients (> _12 years, uncontrolled with medium-to-high-dose ICS plus < _2 additional controllers) with a selfreported medical history of comorbid AR (63.5%; n/N51,207/1,902) or without comorbid AR assessed the effect of add-on dupilumab 200mg or 300mg or matched placebo every 2 weeks (q2w) on the annualized rate of severe exacerbations and forced expiratory volume in 1 second (FEV 1 RATIONALE: Allergic rhinitis (AR), a common type 2 comorbidity in asthma patients, contributes to increased overall disease burden. Dupilumab, a fully human, VelocImmune Ò -derived anti-interleukin-(IL)-4Ra mAb that inhibits signaling of IL-4/IL-13, key drivers of type 2 inflammation, is approved for treatment of adults with inadequately controlled, moderate-to-severe atopic dermatitis. In the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), dupilumab every 2 weeks versus matched placebo suppressed biomarkers of type 2 inflammation in patients with uncontrolled, moderate-to-severe asthma and improved health-related quality of life for those with AR. This posthoc analysis assessed dupilumab's effect on biomarkers in asthma patients with AR. METHODS: 63.5% of patients (n/N51,204/1,897) self-reported medical history of AR, a clinical diagnosis was not recorded. Baseline levels/ change from baseline during the 52-week treatment were assessed for FeNO, total IgE, and Eotaxin-3. RESULTS: At baseline, AR (vs non-AR) patients had higher IgE levels; other biomarkers were similar between groups. Biomarker levels were significantly suppressed in all dupilumab-treated groups vs placebo by Week 12. At Week 52, dupilumab 200/300mg (vs matched placebo) significantly suppressed, in AR and non-AR patients, FeNO(median percentage change -39.0/-38.9 vs -6.3/-16.0 and -30.4/-32.1 vs -5.9/ 0.0), IgE(-71.6/-71.3 vs 0.0/-9.2 and -64.3/-67.8 vs -6.6/0.5), and eotaxin-3(-36.9/-39.9 vs 0.0/-4.6 and -33.6/-37.8 vs 2.6/0.99) (all P<0.0001). The most common AE, with higher frequency in dupilumab versus placebo, was injection-site reactions (15%/18% vs 5%/10%). CONCLUSIONS: Dupilumab demonstrated broad suppression of airways and systemic biomarkers of type 2 inflammation in asthma patients with and without AR.
